Loading
A phase 1/2 trial of ODX (Osteodex) in multiple myeloma, run by DexTech Medical AB, now recruiting.
Study of ODX (OsteoDex) in Multiple Myeloma is a phase 1/2 interventional study registered as NCT06616389 by DexTech Medical AB, with 12 participants planned, started 2023-11-29 and due to reach its primary completion in 2026-01-30. Interventions recorded: ODX (Osteodex).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/